X
[{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Shows Interim Results from Registration-Enabling Trial of Cosibelimab in Cutaneous Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Biologics and Checkpoint Therapeutics Expand Manufacturing Partnership for Cosibelimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Announces Positive Interim Results from RegistrationEnabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.1 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced at-the-Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$11.1 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced at-the-Market","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Checkpoint Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Declines to Approve Checkpoint Therapeutics' Skin Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Checkpoint Therapeutics
Filters
Companies By Therapeutic Area
Details:
The net proceeds will be used in the development of CK-301 (cosibelimab), which is an anti-programmed death-ligand for the treatment of patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma.
Lead Product(s):
Cosibelimab
Therapeutic Area: Oncology
Product Name: CK-301
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
H.C. Wainwright & Co.
Deal Size: $14.0 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
January 29, 2024
Details:
CK-301 (cosibelimab) is a fully-human mAb of IgG1 subtype that directly binds to PD-L1 and blocks the PDL1 interaction with the PD-1 and B7.1 receptors. It is under phase 3 clinical development for the treatment of cutaneous squamous cell carcinoma.
Lead Product(s):
Cosibelimab
Therapeutic Area: Oncology
Product Name: CK-301
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 18, 2023
Details:
Checkpoint intends to use the proceeds for the manufacturing of CK-301 (cosibelimab), a potential best-in-class anti-PD-L1 antibody being developed in patients with selected recurrent or metastatic cancers.
Lead Product(s):
Cosibelimab
Therapeutic Area: Oncology
Product Name: CK-301
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
H.C. Wainwright & Co.
Deal Size: $11.1 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
October 02, 2023
Details:
Checkpoint intends to use the net proceeds for the manufacturing of CK-301 (cosibelimab), a potential best-in-class anti-PD-L1 antibody, being developed for advanced cutaneous squamous cell carcinoma.
Lead Product(s):
Cosibelimab,Cisplatin ,Pemetrexed
Therapeutic Area: Oncology
Product Name: CK-301
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
H.C. Wainwright & Co.
Deal Size: $10.0 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
July 31, 2023
Details:
CK-301 (cosibelimab) is a fully-human mAb of IgG1 subtype that directly binds to PD-L1 and blocks the PDL1 interaction with the PD-1 and B7.1 receptors, which removes the suppressive effects of PD-L1 on anti-tumor CD8+ T-cells to restore the cytotoxic T cell response.
Lead Product(s):
Cosibelimab
Therapeutic Area: Oncology
Product Name: CK-301
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 27, 2023
Details:
Checkpoint intends to use the net proceeds for the manufacturing of CK-301 (cosibelimab), a fully human monoclonal antibody of IgG1 subtype that directly binds to PD-L1 and certain pre-commercial activities in anticipation of potential approval and commercial launch.
Lead Product(s):
Cosibelimab,Pemetrexed ,Cisplatin
Therapeutic Area: Oncology
Product Name: CK-301
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
H.C. Wainwright & Co.
Deal Size: $10.0 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
May 23, 2023
Details:
Checkpoint intends to use the net proceeds of this offering for the manufacturing of CK-301 (cosibelimab) and certain pre-commercial activities in anticipation of potential approval and commercial launch.
Lead Product(s):
Cosibelimab,Pemetrexed ,Cisplatin
Therapeutic Area: Oncology
Product Name: CK-301
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
H.C. Wainwright & Co.
Deal Size: $6.1 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
March 31, 2023
Details:
CK-301 (cosibelimab) is a fully-human mAb of IgG1 subtype that directly binds to PD-L1 and blocks the PDL1 interaction with the PD-1 and B7.1 receptors, which removes the suppressive effects of PD-L1 on anti-tumor CD8+ T-cells to restore the cytotoxic T cell response.
Lead Product(s):
Cosibelimab,Pemetrexed ,Cisplatin
Therapeutic Area: Oncology
Product Name: CK-301
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 02, 2023
Details:
Checkpoint intends to use the net proceeds for the manufacturing of CK-301 (cosibelimab), a potential best-in-class anti-PD-L1 antibody, and certain pre-commercial activities in anticipation of potential approval and commercial launch.
Lead Product(s):
Cosibelimab,Pemetrexed ,Cisplatin
Therapeutic Area: Oncology
Product Name: CK-301
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
H.C. Wainwright & Co.
Deal Size: $7.5 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
February 21, 2023
Details:
CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors.
Lead Product(s):
Cosibelimab,Pemetrexed ,Cisplatin
Therapeutic Area: Oncology
Product Name: CK-301
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
H.C. Wainwright & Co.
Deal Size: $7.5 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
December 15, 2022